Cannabidiol Oral Solution 100 mg/ml
First cannabis-based medicine approved by ANMAT in Argentina
Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC), for patients from two years of age.
PATIENT INFORMATION
COMPOSITION OF CONVUPIDIOL ®
Cannabidiol
Pharmaceutical-grade active ingredient. Non-synthetic. ≥99.6% purity in API.
Extracted from the aerial parts of the Cannabis sativa L., plant, of a specific variety whose biogenesis is perfectly known.
Good Agricultural and Collection Practices. Obtained under the standards of Good Cultivation and Collection Practices for medicinal plants (GACP).
Good Manufacturing Practices Prepared with GMP certification issued by the competent European Health Authority.
ALCOHOL-FREE.
SUCRALOSE-FREE.
Convupidiol ® includes:

2 Reusable oral dosers:

  • 1 ml, ideal for administering doses of 1 ml or less.
  • 5 ml, ideal for administering doses greater than 1 ml.
  • With built-in unique adapter, for both oral dispensers.

EXCIPIENTS

  • Pharmaceutical grade sesame oil (USP coded).
  • Vanilla flavor.
DO NOT REFRIGERATE. DO NOT FREEZE.
Do not store in refrigerator or freezer.
The stability studies conducted have allowed us to quantify the product's quality over time, ensuring the detection of impurities and degradation products well below the limits.
0.017% THC (Tetrahydrocannabinol) = 5 times lower than the specified limit.
TWO PRESENTATIONS
70 ml bottle
7000 mg CBD per bottle
|
35 ml bottle
3500 mg CBD per bottle

THERE IS CURRENTLY NO CONCLUSIVE EVIDENCE REGARDING THE EFFICACY OF CANNABIDIOL IN ANY DISEASE OTHER THAN THE APPROVED INDICATIONS.

Treatment with CONVUPIDIOL® should be initiated and supervised by physicians experienced in the treatment of epilepsy.

SALE UNDER FILED PRESCRIPTION.

© 2025 Alef Medical Argentina. All rights reserved